Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Grifols SA ADR

GRFS
Current price
7.08 USD +0.05 USD (+0.71%)
Last closed 6.55 USD
ISIN US3984384087
Sector Healthcare
Industry Drug Manufacturers - General
Exchange NASDAQ
Capitalization 5 695 626 240 USD
Yield for 12 month +12.38 %
1Y
3Y
5Y
10Y
15Y
GRFS
21.11.2021 - 28.11.2021

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It also markets diagnostic testing equipment, reagents, and other equipment; offers biological products and manufacturing services; and manufactures and sells plasma to third parties. In addition, the company offers Yimmugo IDP, an immunology drug; Yimmugo PTI, a hematology drug; and Prolastin vials, a pulmonology drug. Further, it develops Xembify Pre-filled syringes, Gamunex Bags, and FlexBag; Xembify Biweekly dosing, Fibrinogen, and VISTASEAL; Prolastin-C AADT and Fostamatinib; Xembify " CLL, Albumina 20% and 5%, and Trimodulin; Alfa-1 AT 15%, GRF6019, GRF6021, Aßvac402, AKST4290, and AKST4290; GIGA 2339 and GIGA564; and recIG, Alfa-1 AT - in non-cystic fibrosis bronchiectasis, and OSIG that are in pre-clinical stage. It has collaboration agreements with Canadian Blood Services to supply grains of Immunoglobulin. The company was founded in 1909 and is headquartered in Barcelona, Spain. Address: Avinguda de la Generalitat 152-158, Barcelona, Spain, 08174

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

10.84 USD

P/E ratio

27.23

Dividend Yield

Current Year

+8 202 217 393 USD

Last Year

+7 496 667 315 USD

Current Quarter

+2 246 975 792 USD

Last Quarter

+2 039 023 292 USD

Current Year

+3 178 063 529 USD

Last Year

+2 641 471 090 USD

Current Quarter

+871 688 496 USD

Last Quarter

+826 495 671 USD

Key Figures GRFS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 1 608 263 040 USD
Operating Margin TTM 21.43 %
Price to Earnings 27.23
Return On Assets TTM 3.89 %
PEG Ratio 0.23
Return On Equity TTM 2.64 %
Wall Street Target Price 10.84 USD
Revenue TTM 7 212 382 208 USD
Book Value 8.65 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 11.70 %
Dividend Yield
Gross Profit TTM 2 847 698 944 USD
Earnings per share 0.26 USD
Diluted Eps TTM 0.26 USD
Most Recent Quarter IV 2024
Quarterly Earnings Growth YOY 82.30 %
Profit Margin 2.18 %

Dividend Analytics GRFS

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

23.32 %

Dividend History GRFS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date 03.06.2021
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years 0
Consistent Years 0
Continuous Dividends 0
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor 2:1
Payout Ratio
Last Split Date 04.01.2016

Stock Valuation GRFS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 27.23
Forward PE 11.20
Enterprise Value Revenue 1.95
Price Sales TTM 0.79
Enterprise Value EBITDA 9.49
Price Book MRQ 0.73

Financials GRFS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators GRFS

For 52 weeks

5.79 USD 9.96 USD
50 Day MA 7.50 USD
Shares Short Prior Month 2 706 093
200 Day MA 7.96 USD
Short Ratio 2.39
Shares Short 2 959 434
Short Percent 0.40 %